GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (MEX:2269) » Definitions » Other Operating Expense

WuXi Biologics (Cayman) (MEX:2269) Other Operating Expense : MXN-628 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is WuXi Biologics (Cayman) Other Operating Expense?

WuXi Biologics (Cayman)'s Other Operating Expense for the six months ended in Dec. 2024 was MXN-257 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was MXN-628 Mil.

WuXi Biologics (Cayman)'s quarterly Other Operating Expense declined from Dec. 2023 (MXN-177 Mil) to Jun. 2024 (MXN-370 Mil) but then increased from Jun. 2024 (MXN-370 Mil) to Dec. 2024 (MXN-257 Mil).

WuXi Biologics (Cayman)'s annual Other Operating Expense increased from Dec. 2022 (MXN-530 Mil) to Dec. 2023 (MXN-469 Mil) but then declined from Dec. 2023 (MXN-469 Mil) to Dec. 2024 (MXN-678 Mil).


WuXi Biologics (Cayman) Other Operating Expense Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Other Operating Expense Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -420.25 -444.24 -530.38 -469.46 -677.58

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -231.66 -294.75 -176.77 -370.36 -257.46

WuXi Biologics (Cayman) Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was MXN-628 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi Biologics (Cayman) Other Operating Expense Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) Business Description

Traded in Other Exchanges
Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologic global contract development and manufacturing organizations. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 18.7 billion. North America represented 57.3% of total revenue in 2024. The firm has a "follow and win the molecule" strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing.

WuXi Biologics (Cayman) Headlines

No Headlines